tradingkey.logo
tradingkey.logo
검색

Organon & Co

OGN
관심 목록에 추가
13.475USD
+0.025+0.19%
종가 06/24, 16:00ET시세는 15분 지연됩니다
3.50B시가총액
14.27P/E TTM

자세한 내용은 Organon & Co 회사

Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.

Organon & Co 정보

종목 코드 OGN
회사 이름Organon & Co
상장일May 14, 2021
CEOMorrissey (Joseph T)
직원 수10000
유형Ordinary Share
회계 연도 종료May 14
주소30 Hudson Street
도시JERSEY CITY
증권 거래소NASDAQ OMX NASDAQ Basic NYSE
국가United States of America
우편 번호07302
전화15514306000
웹사이트https://www.organon.com/
종목 코드 OGN
상장일May 14, 2021
CEOMorrissey (Joseph T)

Organon & Co의 회사 임원진

이름
이름/직위
직위
주식 보유
변동
Mr. Matthew M. (Matt) Walsh
Mr. Matthew M. (Matt) Walsh
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
212.75K
--
Ms. Rachel A. Stahler
Ms. Rachel A. Stahler
Executive Vice President, Chief Digital and Growth Officer
Executive Vice President, Chief Digital and Growth Officer
116.52K
+0.36%
Mr. Aaron Falcione
Mr. Aaron Falcione
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
101.67K
+4.83%
Mr. Kirke Weaver
Mr. Kirke Weaver
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
92.70K
+0.06%
Mr. Vittorio Nisita
Mr. Vittorio Nisita
Executive Vice President, Head of Enterprise Services & Solutions
Executive Vice President, Head of Enterprise Services & Solutions
70.86K
+5.78%
Ms. Rochelle B. (Shelly) Lazarus
Ms. Rochelle B. (Shelly) Lazarus
Independent Director
Independent Director
633.00
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Independent Director
Independent Director
2.00
--
Mr. Robert A. (Bob) Essner
Mr. Robert A. (Bob) Essner
Lead Independent Director
Lead Independent Director
--
--
Ms. Cynthia M. Patton
Ms. Cynthia M. Patton
Independent Director
Independent Director
--
--
Ms. Grace M. Puma Whiteford
Ms. Grace M. Puma Whiteford
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Matthew M. (Matt) Walsh
Mr. Matthew M. (Matt) Walsh
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
212.75K
--
Ms. Rachel A. Stahler
Ms. Rachel A. Stahler
Executive Vice President, Chief Digital and Growth Officer
Executive Vice President, Chief Digital and Growth Officer
116.52K
+0.36%
Mr. Aaron Falcione
Mr. Aaron Falcione
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
101.67K
+4.83%
Mr. Kirke Weaver
Mr. Kirke Weaver
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
92.70K
+0.06%
Mr. Vittorio Nisita
Mr. Vittorio Nisita
Executive Vice President, Head of Enterprise Services & Solutions
Executive Vice President, Head of Enterprise Services & Solutions
70.86K
+5.78%
Ms. Rochelle B. (Shelly) Lazarus
Ms. Rochelle B. (Shelly) Lazarus
Independent Director
Independent Director
633.00
--

자주 묻는 질문

Organon & Co의 상위 5대 주주는 누구인가요?

Organon & Co의 상위 5대 주주는 다음과 같습니다: Mr. Matthew M. (Matt) Walsh

Organon & Co(OGN)의 주식을 보유한 기관은 몇 개입니까?

2026Q1 기준으로, Organon & Co의 주식을 보유한 기관은 총 1398곳이며, 이들이 보유한 주식의 총 가치는 약 239.27M로 전체 발행 주식의 91.12%를 차지합니다. 이는 2025Q4 대비 -3985201.00 증가한 수치입니다.

Organon & Co의 최대 수익원은 무엇인가요?

2026Q1 기준, Organon & Co의 Women’s Health 부문이 가장 높은 매출을 기록했으며, 금액은 1.75B로 전체 매출의 28.19%를 차지했습니다.
KeyAI